ALLO Smart Money
Allogene Therapeutics, Inc.
1W: -7.5%
1M: -24.5%
3M: -32.0%
YTD: -8.9%
1Y: +2.5%
3Y: -59.0%
5Y: -92.2%
$1.23
+0.02 (+1.65%)
Pre-Market: $1.27 (+0.04, +3.25%)
Weekly Expected Move ±6.5%
$1
$1
$1
$1
$1
Credit Risk of going bust: higher than 75% of companies Debt: 14.2% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the third-riskiest tenth, about 1 in 140 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.03 (down 97%), Allogene Therapeutics, Inc. would be worth roughly what it owes.
Total debt $70.4M against a stock market value of $425.0M.
Distance to default 3.04 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $35.2M (short-term plus half of long-term), stock volatility 82.3%; Altman Z'' -6.73. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.03 (down 97%), Allogene Therapeutics, Inc. would be worth roughly what it owes.
Total debt $70.4M against a stock market value of $425.0M.
Distance to default 3.04 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $35.2M (short-term plus half of long-term), stock volatility 82.3%; Altman Z'' -6.73. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
🏦 Institutional Activity
Latest: Q2 2026239
Institutions Holding
+20 vs prior
152.0%
Ownership
+50.56%
33
New
98
Increased
80
Reduced
30
Closed
👔 Insider Trades
19 records| Date | Name | Title | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-21 | Parker Geoffrey M. | officer: chief financial officer | S-Sale | 36,342 | $1.34 | $49K | Filing |
| 2026-08-21 | Douglas Earl Martin | officer: svp, general counsel | S-Sale | 29,697 | $2.12 | $63K | Filing |
| 2026-03-16 | Beneski Benjamin Machinas | officer: svp, chief technical officer | S-Sale | 4,835 | $2.47 | $12K | Filing |
| 2026-03-16 | Chang David D | officer: president and ceo | S-Sale | 47,763 | $2.47 | $118K | Filing |
| 2026-03-02 | Beneski Benjamin Machinas | officer: svp, chief technical officer | S-Sale | 7,132 | $2.60 | $19K | Filing |
| 2026-02-02 | Douglas Earl Martin | officer: svp, general counsel | S-Sale | 22,900 | $1.76 | $40K | Filing |
| 2026-02-02 | Roberts Zachary | officer: evp of r&d | S-Sale | 35,700 | $1.77 | $63K | Filing |
| 2026-02-02 | Yoshiyama Annie | officer: svp, finance | S-Sale | 4,167 | $1.72 | $7K | Filing |
| 2026-02-02 | Parker Geoffrey M. | officer: chief financial officer | S-Sale | 24,001 | $1.76 | $42K | Filing |
| 2026-02-02 | Chang David D | officer: president and ceo | S-Sale | 95,269 | $1.80 | $171K | Filing |
| 2026-02-02 | Beneski Benjamin Machinas | officer: svp, chief technical officer | S-Sale | 7,549 | $1.73 | $13K | Filing |
| 2026-01-21 | Roberts Zachary | officer: evp of r&d | S-Sale | 26,269 | $1.56 | $41K | Filing |
| 2025-11-17 | Beneski Benjamin Machinas | officer: svp, chief technical officer | S-Sale | 786 | $1.22 | $959 | Filing |
| 2025-10-21 | Parker Geoffrey M. | officer: chief financial officer | S-Sale | 36,744 | $1.26 | $46K | Filing |
| 2025-06-10 | MESSEMER DEBORAH M. | director | S-Sale | 36,885 | $1.42 | $52K | Filing |
| 2025-04-21 | Yoshiyama Annie | officer: svp, finance | S-Sale | 9,601 | $1.41 | $14K | Filing |
| 2025-03-14 | Beneski Benjamin Machinas | officer: svp, chief technical officer | S-Sale | 5,488 | $1.98 | $11K | Filing |
| 2025-03-14 | Chang David D | officer: president and ceo | S-Sale | 46,668 | $1.96 | $91K | Filing |
| 2025-03-01 | Beneski Benjamin Machinas | officer: svp, chief technical officer | A-Grant/Award | 31,755 | $— | $0 | Filing |
🏛️ Congressional Trades
0 records| Date | Politician | Chamber | Type | Amount | Filing |
|---|---|---|---|---|---|
| No congressional trades found | |||||
🏦 Top Institutional Holders
20 holders| Holder | Shares | Value | Date Reported | Filing | |
|---|---|---|---|---|---|
| BlackRock, Inc. | 30,146,963 | $63M | +11,055,868 | 2026-06-30 | Filing |
| Pfizer Inc | 22,032,040 | $47M | — | 2026-06-30 | Filing |
| Frazier Life Sciences Management, L.P. | 22,446,668 | $47M | +18,650,000 | 2026-06-30 | Filing |
| STATE STREET CORP | 19,025,826 | $40M | +10,365,520 | 2026-06-30 | Filing |
| TPG GP A, LLC | 18,716,306 | $39M | — | 2026-06-30 | Filing |
| Sio Capital Management, LLC | 13,323,431 | $28M | +13,323,431 | 2026-06-30 | Filing |
| PRIMECAP MANAGEMENT CO/CA | 13,123,440 | $27M | +4,743,600 | 2026-06-30 | Filing |
| VANGUARD CAPITAL MANAGEMENT LLC | 12,166,636 | $25M | +5,245,286 | 2026-06-30 | Filing |
| FMR LLC | 12,009,043 | $25M | +10,419,213 | 2026-06-30 | Filing |
| CITADEL ADVISORS LLC | 10,087,770 | $21M | +3,294,150 | 2026-06-30 | Filing |
| TWO SIGMA INVESTMENTS, LP | 7,784,348 | $16M | +2,408,892 | 2026-06-30 | Filing |
| GEODE CAPITAL MANAGEMENT, LLC | 7,049,328 | $15M | +2,925,150 | 2026-06-30 | Filing |
| GOLDMAN SACHS GROUP INC | 6,148,959 | $13M | +3,382,715 | 2026-06-30 | Filing |
| GordonMD Global Investments LP | 5,298,000 | $11M | +3,868,000 | 2026-06-30 | Filing |
| MARSHALL WACE, LLP | 5,095,408 | $11M | +1,647,424 | 2026-06-30 | Filing |
| Patient Square Capital LP | 5,050,000 | $11M | +1,600,000 | 2026-06-30 | Filing |
| Aberdeen Group plc | 5,001,752 | $10M | +3,539,533 | 2026-06-30 | Filing |
| MILLENNIUM MANAGEMENT LLC | 4,843,889 | $10M | +1,521,836 | 2026-06-30 | Filing |
| D. E. Shaw & Co., Inc. | 4,710,735 | $10M | +1,946,959 | 2026-06-30 | Filing |
| MORGAN STANLEY | 4,509,962 | $9M | +3,511,117 | 2026-06-30 | Filing |